INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.1 USD | +0.42% |
|
+7.61% | -9.06% |
| May. 15 | Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM | |
| May. 13 | Equities Close Mixed as Markets Weigh Consumer Inflation Survey | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.08B | Sales 2025 * | 4.52B | Capitalization | 12.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 759M | Net income 2025 * | 963M | EV / Sales 2024 * | 2.11 x |
| Net cash position 2024 * | 4.19B | Net cash position 2025 * | 5.41B | EV / Sales 2025 * | 1.64 x |
| P/E ratio 2024 * |
17.6
x | P/E ratio 2025 * |
14.2
x | Employees | 2,524 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Incyte Corporation
More recommendations
More press releases
More news
| 1 day | +0.42% | ||
| 1 week | +7.61% | ||
| Current month | +9.70% | ||
| 1 month | +8.10% | ||
| 3 months | -1.48% | ||
| 6 months | +5.21% | ||
| Current year | -9.06% |
1 week
56.37
58.93
1 month
50.3558.93
Current year
50.3567.37
1 year
50.2767.37
3 years
50.2788.26
5 years
50.27110.37
10 years
43.86153.15
| Managers | Title | Age | Since |
|---|---|---|---|
Herve Hoppenot
CEO | Chief Executive Officer | 64 | 14-01-12 |
| Director of Finance/CFO | 53 | 19-02-10 | |
Pablo Cagnoni
PSD | President | 60 | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 00-12-31 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 19-12-15 |
| Director/Board Member | 70 | 15-01-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.55% | 254 M€ | +10.97% | - | |
| 2.94% | 1 M€ | +0.15% | - | |
| 2.88% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 57.1 | +0.42% | 1,618,342 |
| 24-05-16 | 56.86 | -0.33% | 3,042,675 |
| 24-05-15 | 57.05 | 0.00% | 3,395,238 |
| 24-05-14 | 57.05 | -0.95% | 2,734,988 |
| 24-05-13 | 57.6 | +8.56% | 7,237,381 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-06-12
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.1
USD
Average target price
73.35
USD
Spread / Average Target
+28.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.06% | 12.82B | |
| -2.32% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B | |
| -6.32% | 8.35B |
- Stock Market
- Equities
- INCY Stock
